outperform price
hub da club
take close fiscal year solid result
although ep guidanc midpoint lighter side
vs street number note embed conservat
assum favor prior-year reserv develop
repeal hif ad increment headwind coupl
penni first full year aet rearview
look forward see progress
healthhub roll-out data product along
sign traction commerci employ strong net
new busi win client retent pbm profit
optimist base well look continu
de-lever eventu step capit return
maintain estim tweak price target
pleas see confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
growth driven increas volum ingeniorx onboard brand inflat
fe sale increas increas health beauti
retail declin expect due reimburs pressur
hcb line expect
strong growth govern product
line
hcb expens higher due readi invest cost
expect lowest earn year due season
hb lowest fourth quarter
benefit enterpris modern ramp cours year synergi
radic throughout year
bn cash repay debt
repaid bn net lt debt sinc aet transact
bn return dividend year
low-msd growth expect
mm synergi previous
bn cash oper
payment dividend
bn avail debt paydown
capital-expenditure bn
expect reach leverag level
weight averag share continu increas due comp
buy back share
complet renew contract sell season
profit pbm
improv sell season improv purchas econom continu drive
segment profit improv modern effort also aid profit improv pbm
work hard reduc rebat exposureon track
narrow guidanc
focu area technolog ration number applic use across
enterpris product improv optim call center develop center
excel better patient care
impact rebat guarante greatest
still hw less expect immateri
mitig portion hw work client adopt complet
driven solid script growth improv gener impact enterpris
modern disproportion benefit retail segment vs other
work reposit fe toward health beauti also roll
primari care healthhub
sell season
complet thathigh retent rate
nurs practition treat treat pcp offic
bn renew sell season
dont expect overcom sell season loss like
new zero co-pay option diabet patient avail caremark aetna custom
wellcar contract extend anoth three-year period effect
 contract renew three-year period start larger portion
busi origin plan
valuat methodolog base mix discount cash flow analysi rel valuat multipl
potenti elev govern scrutini drug price transpar neg impact long-
potenti on-line competit amazon erod front end comp margin us
continu reimburs pressur us eu hit ultim lead total margin
laboratori corp america
articl articl
time dissemin februari
analyst elizabeth anderson suzi yoon amato michael newshel primarili respons prepar research report
attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
